ISSN: 2161-0681

Journal de pathologie clinique et expérimentale

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • JournalTOC
  • Annuaire des périodiques d'Ulrich
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

Do MRE11 Complex and Steroid Hormone Receptors Expressions Impact the Outcomes in High Grade Serous Ovarian Carcinoma?

Mariana F Gayyed, Nehad Reda Abd El-maqsoud, Medhat Monir Soliman and Ahmed K A Abdel-Hakeem

Background: The prognosis and response of treatment of high grade serous ovarian carcinoma can be predicted by using numbers of biological markers.

Aim: The present study aimed of investigating the clinicopathological significance and prognostic value of MRE11, RAD50, ER and PR expressions in high grade serous ovarian carcinoma. The association between doublestrand breaks repair genes (MRE11-RAD50 complex) and steroid hormones receptor (ER and PR) was also studied.

Methods: An immunohistochemical study was performed on 108 high grade serous ovarian carcinoma cases. The expressions of MRE11, RAD50, ER and PR were evaluated and correlated to patients' clinicopathological data.

Results: The results showed that high MRE11, RAD50, ER and PR protein expressions were seen in 51.9%, 70.4%, 66.7% and 31.5%, of high grade serous ovarian carcinoma cases, respectively. MRE11 and RAD50 overexpression was significantly related to high-stage (p=0.012 and p=0.024, respectively), lymph node metastasis (p=0.002 and p=0.008, respectively), negative estrogen expression (p<0.001 for both) and negative progesterone expression (p<0.001 and p=0.002, respectively). MRE11 and RAD50 overexpression was a poor prognostic factor for OS compared with high ER/PR expression in high grade serous ovarian carcinoma patients.

Conclusion: High immunohistochemical expression of MRE11 and RAD50 in high grade serous ovarian carcinomas is related to poor prognosis.